StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) stock

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.33+0.18 (+0.66%)

Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –

Arcutis Biotherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Arcutis Biotherapeutics's pe ratio was 129.0× on Nov 11, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026129.0×–

More Arcutis Biotherapeutics figures

See a number that looks wrong?